CN101835384B - 抗菌组合物 - Google Patents

抗菌组合物 Download PDF

Info

Publication number
CN101835384B
CN101835384B CN200880110119.7A CN200880110119A CN101835384B CN 101835384 B CN101835384 B CN 101835384B CN 200880110119 A CN200880110119 A CN 200880110119A CN 101835384 B CN101835384 B CN 101835384B
Authority
CN
China
Prior art keywords
phage
antiseptic composition
bacterium
mutant
bacteria
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200880110119.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN101835384A (zh
Inventor
贾莹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novolytics Ltd
Original Assignee
Novolytics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0719438A external-priority patent/GB0719438D0/en
Priority claimed from GB0800790A external-priority patent/GB0800790D0/en
Application filed by Novolytics Ltd filed Critical Novolytics Ltd
Publication of CN101835384A publication Critical patent/CN101835384A/zh
Application granted granted Critical
Publication of CN101835384B publication Critical patent/CN101835384B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/40—Viruses, e.g. bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/36—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/30—Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Agronomy & Crop Science (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CN200880110119.7A 2007-10-04 2008-10-03 抗菌组合物 Expired - Fee Related CN101835384B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0719438A GB0719438D0 (en) 2007-10-04 2007-10-04 Anti-bacteria compositions
GB0719438.4 2007-10-04
GB0800790A GB0800790D0 (en) 2008-01-16 2008-01-16 Anti-bacteria compositions
GB0800790.8 2008-01-16
PCT/GB2008/003363 WO2009044163A2 (en) 2007-10-04 2008-10-03 Anti-bacteria compositions

Publications (2)

Publication Number Publication Date
CN101835384A CN101835384A (zh) 2010-09-15
CN101835384B true CN101835384B (zh) 2014-07-16

Family

ID=40526766

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880110119.7A Expired - Fee Related CN101835384B (zh) 2007-10-04 2008-10-03 抗菌组合物

Country Status (8)

Country Link
US (2) US20110182863A1 (https=)
EP (1) EP2197284B1 (https=)
JP (2) JP2011501740A (https=)
CN (1) CN101835384B (https=)
AU (1) AU2008306626B2 (https=)
CA (1) CA2700646C (https=)
ES (1) ES2632367T3 (https=)
WO (1) WO2009044163A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010212280B2 (en) * 2009-08-12 2015-09-24 Buddhist Tzu Chi Medical Foundation Phage of acinetobacter Baumannii
CN103458694A (zh) * 2011-04-01 2013-12-18 通用电气公司 用于治理微生物诱导的腐蚀和环境损害及用于改进废水处理工艺的方法和组合物
GB201119167D0 (en) 2011-11-07 2011-12-21 Novolytics Ltd Novel bachteriophages
DE102013106455A1 (de) 2013-06-20 2014-12-24 Airbus Defence and Space GmbH Verfahren zur Dekontamination von bakteriologischen Verunreinigungen
US10517908B2 (en) 2015-08-13 2019-12-31 Armata Pharmaceuticals, Inc. Therapeutic bacteriophage compositions
EP3436041B1 (en) 2016-03-31 2023-05-24 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
AU2017240064B8 (en) 2016-03-31 2021-11-11 Gojo Industries, Inc. Antimicrobial peptide stimulating sanitizing composition
WO2017173240A1 (en) 2016-03-31 2017-10-05 Gojo Industries, Inc. Antimicrobial peptide stimulating cleansing composition
JP2020500860A (ja) 2016-11-23 2020-01-16 ゴジョ・インダストリーズ・インコーポレイテッド プロバイオティック／プレバイオティックな有効成分を含む消毒薬組成物
CN110719784A (zh) 2017-02-13 2020-01-21 阿玛塔制药公司 治疗性噬菌体组合物
CN112218659A (zh) * 2018-01-02 2021-01-12 阿玛塔制药股份有限公司 用于治疗葡萄球菌感染的治疗性噬菌体组合物
WO2019136108A1 (en) 2018-01-02 2019-07-11 Ampliphi Biosciences Corporation Bacteriophage compositions for treating pseudomonas infections
FR3110599B1 (fr) * 2020-05-19 2024-07-26 Vetophage Nouvelles souches de bacteriophages et leurs utilisations
EP3972620A1 (fr) * 2019-05-21 2022-03-30 Vetophage Nouvelles souches de bactériophages et leurs utilisations
WO2024190909A1 (ja) 2023-03-15 2024-09-19 国立感染症研究所長が代表する日本国 組換えファージ及びその調製方法
EP4720263A1 (en) * 2023-06-01 2026-04-08 University of Florida Research Foundation, Incorporated Phage therapy utilizing a unique cocktail of pseudomonas aeruginosa phages
CN118165942B (zh) * 2024-03-22 2024-12-13 青岛润达生物科技有限公司 一株沙门氏菌噬菌体rdp-sa-22022及其连续化生产工艺和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001050872A3 (en) * 2000-01-11 2001-12-20 Intralytix Inc Method for produce sanitation using bacteriophages
WO2004004495A1 (en) * 2002-07-08 2004-01-15 Exponential Biotherapies, Inc. Virulent phages to control listeria monocytogenes in foodstuffs and in food processing plants
CN1643139A (zh) * 2002-03-25 2005-07-20 沃里克大学 抗菌剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957686A (en) * 1990-02-06 1990-09-18 Norris Alan H Use of bacteriophages to inhibit dental caries
US5811093A (en) * 1994-04-05 1998-09-22 Exponential Biotherapies, Inc. Bacteriophage genotypically modified to delay inactivations by the host defense system
WO1995027043A1 (en) * 1994-04-05 1995-10-12 Exponential Biotherapies, Inc. Antibacterial therapy with genotypically modified bacteriophage
US6335012B1 (en) * 1997-10-31 2002-01-01 Vincent Fischetti Use of bacterial phage associated lysing enzymes for treating bacterial infections of the mouth and teeth
US20040146490A1 (en) * 2000-04-20 2004-07-29 Mount Sinai Hospital Antibacterial therapy for multi-drug resistant bacteria
DE10342071B4 (de) * 2003-09-10 2006-01-19 Fleischmann, Wilhelm, Dr.med. Vorrichtung und Verfahren zur Applikation von Wïrkstoffen an eine Wundoberfläche
US20060153811A1 (en) * 2005-01-10 2006-07-13 Jackson Lee E Use of viruses and virus-resistant microorganisms for controlling microorganism populations
KR100781669B1 (ko) * 2006-06-20 2007-12-03 주식회사 인트론바이오테크놀로지 황색포도상구균 특이적 사멸능을 갖는 박테리오파지

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001050872A3 (en) * 2000-01-11 2001-12-20 Intralytix Inc Method for produce sanitation using bacteriophages
WO2001051066A3 (en) * 2000-01-11 2002-01-10 Intralytix Inc Reduction in bacterial colonization by administering bacteriophage compositions
CN1643139A (zh) * 2002-03-25 2005-07-20 沃里克大学 抗菌剂
WO2004004495A1 (en) * 2002-07-08 2004-01-15 Exponential Biotherapies, Inc. Virulent phages to control listeria monocytogenes in foodstuffs and in food processing plants

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Phage P68 virion-associated protein 17 displays activity against clinical isolates of Staphylococcus aureus;M. TAKAC;《ANTIMICROBIAL AGENTS AND CHEMOTHERAPY》;20050731;第49卷(第7期);第2934-2936页 *
Potential of the polyvalent anti-Staphylococcus bacteriophage K for control of antibiotic-resistant staphylococci from hospitals;O"FLAHERTY S ET AL;《APPLIED AND ENVIRONMENTAL MICROBIOLOGY》;20050401;第71卷(第4期);第1837页 *

Also Published As

Publication number Publication date
WO2009044163A2 (en) 2009-04-09
JP6053727B2 (ja) 2016-12-27
WO2009044163A3 (en) 2010-02-11
CN101835384A (zh) 2010-09-15
US20110182863A1 (en) 2011-07-28
AU2008306626B2 (en) 2013-05-09
EP2197284B1 (en) 2017-04-12
JP2011501740A (ja) 2011-01-13
US20150216179A1 (en) 2015-08-06
ES2632367T3 (es) 2017-09-12
EP2197284A2 (en) 2010-06-23
JP2015007087A (ja) 2015-01-15
CA2700646A1 (en) 2009-04-09
CA2700646C (en) 2019-10-29
AU2008306626A1 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
CN101835384B (zh) 抗菌组合物
Castillo et al. Propionibacterium (Cutibacterium) acnes bacteriophage therapy in acne: current evidence and future perspectives
AU2010212280B2 (en) Phage of acinetobacter Baumannii
Wang et al. Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant Pseudomonas aeruginosa
Capparelli et al. Selection of an Escherichia coli O157: H7 bacteriophage for persistence in the circulatory system of mice infected experimentally
CN108697744A (zh) 假单胞菌感染的噬菌体疗法
KR100781669B1 (ko) 황색포도상구균 특이적 사멸능을 갖는 박테리오파지
WO2009087356A1 (en) Host range change phage
US20100291041A1 (en) Bacteriophage preparation and use
Erol et al. The effect of phage-antibiotic combination strategy on multidrug-resistant Acinetobacter baumannii biofilms
JP2021508501A (ja) Ｐｓｅｕｄｏｍｏｎａｓ感染症を処置するためのバクテリオファージ組成物
Sandeep Bacteriophage precision drug against bacterial infections
Ali et al. Therapeutic potential of a newly isolated bacteriophage against multi-drug resistant Enterococcus faecalis infections: in vitro and in vivo characterization
Zhao et al. A newly isolated bacteriophage vB8388 and its synergistic effect with aminoglycosides against multi-drug resistant Klebsiella oxytoca strain FK-8388
Kulsuwan et al. Lytic capability of bacteriophages (Family Myoviridae) on Burkholderia pseudomallei
Walter Efficacy and durability of Bacillus anthracis bacteriophages used against spores.
US20040146490A1 (en) Antibacterial therapy for multi-drug resistant bacteria
Dutta et al. Bacteriophage therapy to combat antibiotic resistance: a brief review
AU2015264918A1 (en) Anti-bacteria compositions
Leta et al. Assessment of therapeutic potential of bacteriophages to control Escherichia coli infection in Swiss mice model
Agbo et al. Isolation and analysis of the biological characteristics of a novel bacteriophage vB_SauP_P992 against Staphylococcus aureus
AU2013203570A1 (en) Anti-bacteria compositions
KR102851110B1 (ko) 신규한 스타필로코커스 우레일리티쿠스 박테리오파지 vB_SurP-PSU3 및 이의 용도
Srichaisupakit et al. Characterization of N4-like Pseudomonas Phage vB_Pae-PA14 Isolated from Seawater Sampled in Thailand.
Kasarla et al. Bacteriophage therapy: an alternative to antibiotics in the age of multi-drug resistance

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140716

Termination date: 20161003